A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/00001434/isLanding
下载链接
链接失效反馈官方服务:
资源简介:
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)
提供机构:
Vivli
创建时间:
2018-10-27



